En Banc Rehearing Denied In Pennsylvania Risperdal Punitives Ruling

Mealey's (April 2, 2018, 11:27 AM EDT) -- PHILADELPHIA — The Pennsylvania Superior Court on March 16 denied a motion by Janssen Pharmaceuticals Inc. and Johnson & Johnson to conduct an en banc rehearing of a panel’s recent ruling reversing the trial court’s omnibus prohibition against punitive damages in the state’s Risperdal gynecomastia cases (Timothy Stange v. Janssen Pharmaceuticals, Inc., et al., Nos. 739 EDA 2016 and 1549 EDA 2016, Pa. Super.)....

Related Sections